<DOC>
	<DOCNO>NCT02253901</DOCNO>
	<brief_summary>Study determine pharmacokinetic effect BILR 355 + ritonavir® TRUVADA TRUVADA BILR 355</brief_summary>
	<brief_title>Pharmacokinetic Interaction Between TRUVADA™ BILR 355 BS Plus Ritonavir Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Males Females meet inclusion/exclusion criterion ; female must pregnant nursing , must agree use doublebarrier method birth control ( condoms diaphragm , plus spermicide ) throughout trial ( alone addition method birth control oral contraceptive ) Age ≥18 &lt; 60 year Body Mass Index ( BMI ) ≥18.5 BMI ≤29.9 kg/m2 Ability give sign dated write informed consent prior admission study accordance good clinical practice ( GCP ) local regulation Current ( symptomatic within last 30 day ) medically relevant gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Currently active ( symptomatic within last 30 day ) diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within one month prior administration study drug trial ( review clinical monitor questionable ) Use drug within 10 day prior administration trial , might reasonably influence result trial base knowledge time protocol preparation ( review clinical monitor questionable ) Participation another trial investigational drug within one month prior administration trial Current smoker Alcohol ( 60 g/day ) drug abuse ( positive urine test illicit prescription nonprescription drug drug abuse ) Recent blood donation ( 100 mL within 4 week prior administration trial ) Excessive physical activity ( within 1 week prior study drug administration trial ) Any laboratory value outside normal reference range clinical relevance screening , accord judgment investigator Inability comply dietary regimen require protocol Chronic relevant acute infection Infected hepatitis B hepatitis C virus ( define either hepatitis B surface antigen , hepatitis C antibody positive ) HIV1 infect define positive HIV ELISA test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>